Diego
Arango Del Corro
diegoarango@gomhuvh.esGrupo: GDLF-HUVH
Formación
:1998: Ph.D. in Biology. University College Dublin, Dublin, Ireland.
Publicaciones
:Original articles:
37.- Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, Figueroa M, Melnick A, Kao G, Augenlicht LH and Mariadason JM. HDAC4 promotes growth of colon cancer cells via repression of p21. 2007 Submitted
36.- Jhawer M, Goel S, Wilson AJ, MontagnaC, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez Soler R, Mariadason JM. PIK3CA/PTEN mutation status predicts response of colon cancer cells to the EGFR inhibitor cetuximab. 2007 Cancer Research - in press
35.- Li T, Yang W, Li M, Byun DS, Zhuang M, Nasser S, L’italien K, Arango D, Mariadason JM, and Augenlicht LH. Selenium-Binding Protein 1 Characterizes Intestinal Cell Maturation and Predicts Survival for Patients with Colorectal Cancer. Molecular Nutrition and Food Research 2007 in press
34.- Romero-Giménez J, Dopeso H, Guerra A, Blanco I, Schwartz Jr S, Arango D. Germline hypermethylation of the APC promoter is not a common cause of FAP/AFAP. International Journal of Cancer 2007 Nov 20; [Epub ahead of print] - (Impact Factor: 4.7) –Corresponding Author
33.- Alazzouzi H, SurianoG, Guerra A, Plaja A, Espín E, Armengol M, Alhopuro P, Velho S, Shinomura Y, González-Aguilera JJ, Yamamoto H, Aaltonen L, Moreno V, Capellà G, Peinado MA, Seruca R, Arango D, Schwartz Jr S. Tumor selection advantage of non-dominant negative p53 mutations in homozygous mdm2-snp309 colorectal cancer cells. Journal of Medical Genetics, 2007;44(1):75-80 - (Impact Factor: 4.3)
32.- Laiho P, Kokko A, Vanharanta S, Salovaara R, Sammalkorpi H, Järvinen H, Mecklin JP, Karttunen TJ, Tuppurainen K, Davalos V, Schwartz S Jr. , Arango D, Mäkinen MJ, and Aaltonen LA. Serrated Carcinomas Form a Subclass of Colorectal Cancer with Distinct Molecular Basis. Oncogene, 2007;26(2):312-20 - (Impact Factor: 6.8)
31.- Davalos v, Dopeso H, Velho S, Monteiro Ferreira A, Cirnes L, Díaz-Chico N, Bilbao C, Ramírez R, Rodríguez G, Falcón O, León L, Niessen R, Keller G, Dallenbach-Hellweg G, Espín E, Armengol M, Perucho M2007;26(2):308-11 - (Impact Factor: 6.8) –Corresponding Author
30.- Davalos V, Dopeso H, Castaño J, Wilson AJ, Vilardell F, Romero-Gimenez J, Espín E, Armengol M, Capella G, Mariadason JM, Aaltonen LA, Schwartz Jr. S, Arango D. EPHB4 and survival of colorectal cancer patients. Cancer Research, 2006; 66(18):8943-8948 - (Impact Factor: 8.7) –Corresponding Author
29.- Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Arango D, Aaltonen LA, Schwartz S Jr, Esteller M. A truncating mutation of HDAC2 in human cancers confer resistance to histone deacetylase inhibition. Nature Genetics, 2006;38(5):566-9 - (Impact Factor: 25.8)
28.- Wilson AJ, Byun DS, Smartt H, L’Italien K, Sowa Y, Arango D, Augenlicht LH and. Mariadason JM. Class I Histone deacetylases are upregulated in human colonic tumors and are linked to reduced cell differentiation in vivo and in vitro. Journal of Biological Chemistry 2006 May 12;281(19):13548-58 - (Impact Factor: 5.8)
27.- Paroder V, Spencer SR, Paroder M, Arango D, Schwartz Jr S, Mariadason JM, Augenlicht LH, Eskandari S, and Carrasco N. Na+/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: Molecular characterization of SMCT. Proceedings of the National Academy of Sciences, 2006 May 9;103(19):7270-5 - (Impact Factor: 10.2)
26.- Vanharanta S, Laiho P, Sjöberg J, Leminen A, Arola J, Aittomäki K, Karhu A, Arango D and Aaltonen LA. Global Expression Pattern of FH-deficient Fibroids. Human Molecular Genetics, 2005; 15(1):97-103 - (Impact Factor: 7.8)
25.- Bressin C, Bourgarel-Rey V, Carré M, Pourroy B, Arango D, Braguer D and Barra Y. Decrease in c-Myc expression enhances cancer cells sensitivity to vinblastine. Anti-cancer Drugs, 2006 Feb;17(2):181-187 - (Impact Factor: 1.9)
24.- Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, Wilson AJ, Konrad L, Laiho P, Espín E, Armengol M, Imai K, Yamamoto H, Mariadason JM, Gebert JF, Aaltonen LA, Schwartz S Jr., Arango D. Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Research, 2005; 65(22):10170-3 - (Impact Factor: 8.7) –Corresponding Author
23.- Kokko A, Ylisaukko-oja S, Kiuru M, Takatalo MS, Salmikangas P, Tuimala J, Arango D, Karhu A, Aaltonen LA and Jäntti J. Modeling tumor predisposing FH mutations in yeast; effects on fumarase activity, growth phenotype and gene expression profile. International Journal of Cancer, 2006 Mar 15;118(6):1340-5. - (Impact Factor: 4.7)
22.- Vanharanta S, Laiho P, Sjöberg J, Leminen A, Aittomäki K, Arola J, Arango D and Aaltonen LA. Distinct Expression Profiles in Fumarate Hydratase Deficient Fibroids. Oncogene, 2005; 24: 6545–6554 - (Impact Factor: 6.8)
21.- Alhopuro P, Alazzouzi H, Sammalkorpi H, Salovaara R, Järvinen H, Mecklin JP, Schwartz S Jr., Aaltonen LA and Arango D. SMAD4 and prediction of response to adjuvant therapy in colorectal cancer patients. Clinical Cancer Research, 2005;11: 6311-6316 - (Impact Factor: 6.5) –Corresponding Author
20.- Arango D, Laiho P, Kokko A, Salamrkorpi H, Järvinen H, Mecklin J-P, Salovaara R, Schwartz S Jr., Aaltonen LA. Utilization of microarray profiling to predict prognosis of patients with Dukes C colorectal cancer. Gastroenterology, 2005;129(3):874-84 - (Impact Factor: 13.1) –Corresponding Author
19.- Kruhøffer. Brithish Journal of Cancer, 2005;92(12):2240-8 - (Impact Factor: 4.1)
18.- Hienonen T, Sammalkorpi H, Enholm S, Alhopuro P, Barber TD, Lehtonen R, Nupponen NN, Lehtonen H, Salovaara R, Mecklin JP, Järvinen H, Koistinen R, Arango D, Launonen V, Vogelstein B, Karhu A, and Aaltonen LA. Mutations in two short non-coding mononucleotide repeats in most microsatellite unstable colorectal cancers. Cancer Research, 2005; 65(11):4607-13 - (Impact Factor: 8.7)
17.- Mariadason JM, Yang W, Wilson AJ, Nicholas C, Corner GA and Arango D, Augenlicht LH. Analysis of the Genetic Reprogramming that Defines Differentiation Along the Crypt-Villus Axis. Gastroenterology, 2005;128(4):1081-8 - (Impact Factor: 13.1)
16.- Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Järvinen H, Mecklin JP, Schwartz Jr P, Aaltonen LA and Arango D. SMAD4 protein level as a prognostic marker in colorectal cancer. Clinical Cancer Research, 2005; 11(7):2606-11 - (Impact Factor: 6.5)
15.- Arango D, Wilson AJ, Mariadason JM, Corner GA, Arañes MJ, Nicholas C & Augenlicht LH. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. British Journal of Cancer, 2004; 91(11):1931-46 - (Impact Factor: 4.1) –Corresponding Author
14.- Oliveira C, Westra JL, Arango D, Ollikainen M, Domingo E, Ferreira A, Velho S, Niessen R, Lagerstedt K, Alhopuro P, Laiho P, Veiga I, Teixeira MR, Ligtenberg M, Kleibeuker JH, Sijmons RH, Plukker JT, Imai K, Lage P, Hamelin R, Albuquerque C, Schwartz S Jr, Lindblom A, Peltomaki P, Yamamoto H, Aaltonen LA, Seruca R, Hofstra RM. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline Mismatch Repair defects and hMLH1 methylation status. Human Molecular Genetics, 2004; 13(19):2303-11
37.- Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, Figueroa M, Melnick A, Kao G, Augenlicht LH and Mariadason JM. HDAC4 promotes growth of colon cancer cells via repression of p21. 2007 Submitted
36.- Jhawer M, Goel S, Wilson AJ, MontagnaC, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez Soler R, Mariadason JM. PIK3CA/PTEN mutation status predicts response of colon cancer cells to the EGFR inhibitor cetuximab. 2007 Cancer Research - in press
35.- Li T, Yang W, Li M, Byun DS, Zhuang M, Nasser S, L’italien K, Arango D, Mariadason JM, and Augenlicht LH. Selenium-Binding Protein 1 Characterizes Intestinal Cell Maturation and Predicts Survival for Patients with Colorectal Cancer. Molecular Nutrition and Food Research 2007 in press
34.- Romero-Giménez J, Dopeso H, Guerra A, Blanco I, Schwartz Jr S, Arango D. Germline hypermethylation of the APC promoter is not a common cause of FAP/AFAP. International Journal of Cancer 2007 Nov 20; [Epub ahead of print] - (Impact Factor: 4.7) –Corresponding Author
33.- Alazzouzi H, SurianoG, Guerra A, Plaja A, Espín E, Armengol M, Alhopuro P, Velho S, Shinomura Y, González-Aguilera JJ, Yamamoto H, Aaltonen L, Moreno V, Capellà G, Peinado MA, Seruca R, Arango D, Schwartz Jr S. Tumor selection advantage of non-dominant negative p53 mutations in homozygous mdm2-snp309 colorectal cancer cells. Journal of Medical Genetics, 2007;44(1):75-80 - (Impact Factor: 4.3)
32.- Laiho P, Kokko A, Vanharanta S, Salovaara R, Sammalkorpi H, Järvinen H, Mecklin JP, Karttunen TJ, Tuppurainen K, Davalos V, Schwartz S Jr. , Arango D, Mäkinen MJ, and Aaltonen LA. Serrated Carcinomas Form a Subclass of Colorectal Cancer with Distinct Molecular Basis. Oncogene, 2007;26(2):312-20 - (Impact Factor: 6.8)
31.- Davalos v, Dopeso H, Velho S, Monteiro Ferreira A, Cirnes L, Díaz-Chico N, Bilbao C, Ramírez R, Rodríguez G, Falcón O, León L, Niessen R, Keller G, Dallenbach-Hellweg G, Espín E, Armengol M, Perucho M2007;26(2):308-11 - (Impact Factor: 6.8) –Corresponding Author
30.- Davalos V, Dopeso H, Castaño J, Wilson AJ, Vilardell F, Romero-Gimenez J, Espín E, Armengol M, Capella G, Mariadason JM, Aaltonen LA, Schwartz Jr. S, Arango D. EPHB4 and survival of colorectal cancer patients. Cancer Research, 2006; 66(18):8943-8948 - (Impact Factor: 8.7) –Corresponding Author
29.- Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Arango D, Aaltonen LA, Schwartz S Jr, Esteller M. A truncating mutation of HDAC2 in human cancers confer resistance to histone deacetylase inhibition. Nature Genetics, 2006;38(5):566-9 - (Impact Factor: 25.8)
28.- Wilson AJ, Byun DS, Smartt H, L’Italien K, Sowa Y, Arango D, Augenlicht LH and. Mariadason JM. Class I Histone deacetylases are upregulated in human colonic tumors and are linked to reduced cell differentiation in vivo and in vitro. Journal of Biological Chemistry 2006 May 12;281(19):13548-58 - (Impact Factor: 5.8)
27.- Paroder V, Spencer SR, Paroder M, Arango D, Schwartz Jr S, Mariadason JM, Augenlicht LH, Eskandari S, and Carrasco N. Na+/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: Molecular characterization of SMCT. Proceedings of the National Academy of Sciences, 2006 May 9;103(19):7270-5 - (Impact Factor: 10.2)
26.- Vanharanta S, Laiho P, Sjöberg J, Leminen A, Arola J, Aittomäki K, Karhu A, Arango D and Aaltonen LA. Global Expression Pattern of FH-deficient Fibroids. Human Molecular Genetics, 2005; 15(1):97-103 - (Impact Factor: 7.8)
25.- Bressin C, Bourgarel-Rey V, Carré M, Pourroy B, Arango D, Braguer D and Barra Y. Decrease in c-Myc expression enhances cancer cells sensitivity to vinblastine. Anti-cancer Drugs, 2006 Feb;17(2):181-187 - (Impact Factor: 1.9)
24.- Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, Wilson AJ, Konrad L, Laiho P, Espín E, Armengol M, Imai K, Yamamoto H, Mariadason JM, Gebert JF, Aaltonen LA, Schwartz S Jr., Arango D. Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Research, 2005; 65(22):10170-3 - (Impact Factor: 8.7) –Corresponding Author
23.- Kokko A, Ylisaukko-oja S, Kiuru M, Takatalo MS, Salmikangas P, Tuimala J, Arango D, Karhu A, Aaltonen LA and Jäntti J. Modeling tumor predisposing FH mutations in yeast; effects on fumarase activity, growth phenotype and gene expression profile. International Journal of Cancer, 2006 Mar 15;118(6):1340-5. - (Impact Factor: 4.7)
22.- Vanharanta S, Laiho P, Sjöberg J, Leminen A, Aittomäki K, Arola J, Arango D and Aaltonen LA. Distinct Expression Profiles in Fumarate Hydratase Deficient Fibroids. Oncogene, 2005; 24: 6545–6554 - (Impact Factor: 6.8)
21.- Alhopuro P, Alazzouzi H, Sammalkorpi H, Salovaara R, Järvinen H, Mecklin JP, Schwartz S Jr., Aaltonen LA and Arango D. SMAD4 and prediction of response to adjuvant therapy in colorectal cancer patients. Clinical Cancer Research, 2005;11: 6311-6316 - (Impact Factor: 6.5) –Corresponding Author
20.- Arango D, Laiho P, Kokko A, Salamrkorpi H, Järvinen H, Mecklin J-P, Salovaara R, Schwartz S Jr., Aaltonen LA. Utilization of microarray profiling to predict prognosis of patients with Dukes C colorectal cancer. Gastroenterology, 2005;129(3):874-84 - (Impact Factor: 13.1) –Corresponding Author
19.- Kruhøffer. Brithish Journal of Cancer, 2005;92(12):2240-8 - (Impact Factor: 4.1)
18.- Hienonen T, Sammalkorpi H, Enholm S, Alhopuro P, Barber TD, Lehtonen R, Nupponen NN, Lehtonen H, Salovaara R, Mecklin JP, Järvinen H, Koistinen R, Arango D, Launonen V, Vogelstein B, Karhu A, and Aaltonen LA. Mutations in two short non-coding mononucleotide repeats in most microsatellite unstable colorectal cancers. Cancer Research, 2005; 65(11):4607-13 - (Impact Factor: 8.7)
17.- Mariadason JM, Yang W, Wilson AJ, Nicholas C, Corner GA and Arango D, Augenlicht LH. Analysis of the Genetic Reprogramming that Defines Differentiation Along the Crypt-Villus Axis. Gastroenterology, 2005;128(4):1081-8 - (Impact Factor: 13.1)
16.- Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Järvinen H, Mecklin JP, Schwartz Jr P, Aaltonen LA and Arango D. SMAD4 protein level as a prognostic marker in colorectal cancer. Clinical Cancer Research, 2005; 11(7):2606-11 - (Impact Factor: 6.5)
15.- Arango D, Wilson AJ, Mariadason JM, Corner GA, Arañes MJ, Nicholas C & Augenlicht LH. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. British Journal of Cancer, 2004; 91(11):1931-46 - (Impact Factor: 4.1) –Corresponding Author
14.- Oliveira C, Westra JL, Arango D, Ollikainen M, Domingo E, Ferreira A, Velho S, Niessen R, Lagerstedt K, Alhopuro P, Laiho P, Veiga I, Teixeira MR, Ligtenberg M, Kleibeuker JH, Sijmons RH, Plukker JT, Imai K, Lage P, Hamelin R, Albuquerque C, Schwartz S Jr, Lindblom A, Peltomaki P, Yamamoto H, Aaltonen LA, Seruca R, Hofstra RM. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline Mismatch Repair defects and hMLH1 methylation status. Human Molecular Genetics, 2004; 13(19):2303-11
© 2013